Related Experiment Video

Updated: Jul 20, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Autologous renal cell cancer vaccines using heat shock protein-peptide complexes

Maryam Aalamian1, Ephraim Fuchs, Renu Gupta

  • 1Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231, USA.

Urologic Oncology
|September 12, 2006
PubMed

Insights

Heat shock proteins (HSPs) show promise for treating renal cell carcinoma (RCC). Clinical trials are evaluating HSP-based treatments and vaccines for various stages of RCC, offering new immunotherapeutic options.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Heat shock proteins (HSPs) play a significant role in immune responses.
  • HSPs are being investigated for their therapeutic potential in cancer treatment.
  • Renal cell carcinoma (RCC) is a type of kidney cancer with ongoing research into novel treatments.

Purpose of the Study:

  • To review the scientific rationale for using HSPs in RCC treatment.
  • To discuss the current and future clinical trials involving HSPs for RCC.
  • To compare HSP-based immunotherapies with other approaches for RCC.

Main Methods:

  • Literature review of scientific studies on HSPs and RCC.
  • Analysis of ongoing and planned randomized clinical trials.
  • Evaluation of immunotherapeutic strategies in RCC.

Main Results:

  • Extensive research over two decades supports HSPs' role in immune response.
  • Phase III clinical trials are nearing completion for adjuvant RCC treatment with HSPs.
  • HSP-based vaccines are being tested in advanced RCC stages.

Conclusions:

  • HSPs present a compelling scientific basis for RCC immunotherapy.
  • Clinical trials are crucial for validating HSP efficacy in RCC.
  • HSP-based therapies offer a promising avenue for RCC treatment.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.